Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief ...

We are confident that our heritage, success in the last six years, and the talent of our people will help to further establish Daiichi Sankyo as a trusted partner in UK oncology. About the ...

With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and ...

This is Okuzawa and starting from April, I'll be taking this heavy responsibility of CEO of Daiichi Sankyo. The purpose is to make a contribution to the rich and healthy life for the people in the ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

Narrow-moat Daiichi Sankyo’s third-quarter earnings were ... opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes.

(RTTNews) - British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK ... We are proud to bring Datroway to people living with metastatic HR-positive, HER2-negative breast ...

Daiichi Sankyo has made a little bit of pharma industry ... an aggressive form of brain cancer that affects around 2,500 people in Japan. It's not the first therapy in the oncolytic virus class ...

The benefit of direct oral anticoagulants on stroke risk in patients with prior intracerebral hemorrhage and atrial ...

Trump tariffs on chips and drugs would hit U.S. allies in Asia Worldcategory· January 28, 2025 The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's ...

The FDA has approved AstraZeneca and Daiichi Sankyo’s Datroway (datopotamab deruxtecan or Dato ... We are proud to bring Datroway to people living with metastatic HR-positive, HER2-negative breast ...